A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

July 20, 2022 updated by: Bukwang Pharmaceutical

A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy

An open study to evaluate the safety of apatinib mesylate (YN968D1) 1,000mg monotherapy in patients with unresectable locally advanced or metastatic Gastric cancer failed to standard therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 19 years of age or older
  • Subjects with histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
  • Failure or noncompliance of existing standard treatment without alternative treatment
  • Measurable disease measured by proper image examination defined by RECIST 1.1
  • Life expectancy ≥ 3 months
  • Subject must be suitable for oral administration of study medication
  • Subject who can submit a written consent form before participating in the test
  • Adequate bone marrow, renal, and liver function
  • Electrocorticography(ECOG) performance status ≤ 2
  • Ability and willingness to comply with the study protocol for the duration of the study

Exclusion Criteria:

  • Pregnant or lactating women
  • Therapy with clinically significant systemic anticoagulant or antithrombotic agents within 7 days prior to first scheduled dose of YN968D1
  • Hemoptysis within 3 months prior to first scheduled dose of YN968D1
  • Cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) prior to first scheduled dose of YN968D1
  • Surgery or biopsy within 28 days prior to first scheduled dose of YN968D1
  • Minor surgery within 7 days prior to first scheduled dose of YN968D1
  • Patients who have experience using YN968D1 before
  • Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19
  • Known history of human immunodeficiency virus infection (HIV)
  • Medical history of other cancers (including blood cancer) in the 5 years
  • Radiology therapy to target lesion within 28 days, or diagnosis of other cancer within 14 days prior to first scheduled dose of YN968D1
  • History of bleeding diathesis or bleeding within 14 days prior to enrollment
  • Medical history of clinically significant thrombosis (bleeding or clotting disorder) within the past 3-months
  • History of non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months
  • History of idiopathic or hereditary angioedema, sickle cell or any hemolytic anemia
  • History of uncontrolled hypertension that in the opinion of the investigator
  • Complete Left bundle branch block (LBBB) or bifascicular (RBBB and left anterior or posterior hemi-block)
  • Clinically significant S-T segment or T wave abnormality
  • Abnormal atrial fibrillation
  • History of ECOG or left ventricular ejection fraction (LVEF) abnormality during last 3 months in the opinion of the investigator
  • Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication
  • Congestive heart failure (New York Heart Association class III-IV)
  • History of other significant cardiovascular disease or vascular disease within the last 6 months
  • History of clinically significant glomerulonephritis, biopsy proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies Treatment with an investigational agent within the longest time frame of either 5 half-lives or 30 days of initiating study drug
  • Half-life of other investigator drug is not passed over fivefold or 30 days prior to clinical trial
  • Known recreational substance use or psychiatric illness that, in the opinion of the Investigator, may affect compliance with scheduled visits
  • Known hypersensitivity to YN968D1 or components of the formulation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Apatinib mesylate
1,000mg Apatinib mesylate p.o. qd

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer
Time Frame: First 28 days of dosing
Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.03
First 28 days of dosing

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Adverse events (AEs), Serious AEs (SAEs), clinical laboratory abnormalities, and ECG abnormalities
Time Frame: From date of registration to time of first progressive disease(PD) or death, an average of 1 year
Incidence and severity of treatment-related adverse events reported and their relationship to Apatinib mesylate will be assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3)
From date of registration to time of first progressive disease(PD) or death, an average of 1 year
Duration of Response(Stable disease, partial response or Complete response)
Time Frame: From date of registration to time of first progressive disease(PD) or death, an average of 1 year
Tumor response and progression will be evaluated using RECIST v 1.1.
From date of registration to time of first progressive disease(PD) or death, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Yoon-Koo Kang, PhD, Seoul ASAN Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2016

Primary Completion (Actual)

November 1, 2016

Study Completion (Actual)

March 1, 2019

Study Registration Dates

First Submitted

February 26, 2016

First Submitted That Met QC Criteria

March 16, 2016

First Posted (Estimate)

March 17, 2016

Study Record Updates

Last Update Posted (Actual)

July 22, 2022

Last Update Submitted That Met QC Criteria

July 20, 2022

Last Verified

July 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • BK-AM-GC102

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.